BRIEF published on 08/08/2025 at 02:20, 1 year 2 months ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 1 year 2 months ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 1 year 4 months ago CureVac publie les résultats de son assemblée générale annuelle CureVac Nominations Au Conseil D'administration Commissaires Aux Comptes Technologie De L'ARNm Assemblée Annuelle
BRIEF published on 06/24/2025 at 22:14, 1 year 4 months ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 1 year 4 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
BRIEF published on 05/20/2025 at 13:05, 1 year 5 months ago CureVac Reports Q1 2025 Financials and Business Developments Financial Results Revenue Patents Oncology Pipeline R&D Developments
BRIEF published on 05/20/2025 at 13:05, 1 year 5 months ago CureVac publie ses résultats financiers et ses développements commerciaux pour le premier trimestre 2025 Résultats Financiers Brevets Revenu Pipeline En Oncologie Développements En R&D
PRESS RELEASE published on 05/20/2025 at 13:00, 1 year 5 months ago CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates CureVac announces financial results for Q1 2025 and updates on lung cancer and glioblastoma trials, urinary tract infection vaccine, and mRNA patents. Cash position strong at €438.3 million Financial Results Oncology Pipeline CureVac Q1 2025 MRNA Patents
BRIEF published on 05/15/2025 at 22:15, 1 year 5 months ago CureVac Gains Favorable Patent Decision Against BioNTech BioNTech MRNA Technology CureVac Patent Litigation European Patent Office
BRIEF published on 05/15/2025 at 22:15, 1 year 5 months ago CureVac obtient une décision favorable en matière de brevets contre BioNTech BioNTech CureVac Technologie De L'ARNm Office Européen Des Brevets Litiges En Matière De Brevets
Published on 11/05/2026 at 14:31, 44 minutes ago First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile
Published on 11/05/2026 at 14:20, 55 minutes ago Polaris Renewable Energy Declares Quarterly Dividend
Published on 11/05/2026 at 14:15, 1 hour ago Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook
Published on 11/05/2026 at 14:00, 1 hour 15 minutes ago Horizon Aircraft Signs MOU With Constance Lake First Nation to Bring Lifesaving Medical Aircraft to Remote and Isolated Indigenous Communities
Published on 11/05/2026 at 14:58, 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/05/2026 at 14:56, 18 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 11/05/2026 at 15:01, 13 minutes ago Chiffre d'Affaires du 1er semestre de l'exercice 2026/2027
Published on 11/05/2026 at 10:16, 4 hours 58 minutes ago Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Published on 11/05/2026 at 10:16, 4 hours 58 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
